Review Article
Prognostic Value of FOXM1 in Patients with Malignant Solid Tumor: A Meta-Analysis and System Review
Table 1
Characteristics of eligible studies.
| | Study | Country | Cancer type | Duration | Number | Method | Percent | Follow-up assessment | Quality |
| |
Bektas et al. 2008 [16] | Germany | BC | 1994–2002 | 204 | IHC | 72.3% | SC | 0.80 (0.30–2.11) | 9 | | Sanders et al. 2013 [11] | UK | BC; ER+ | NR | 455 | Microarray | 49.9% | HR | 3.51 (2.12–5.81) | 9 | | Bergamaschi et al. 2014 [21] | USA | BC; ER+ | NR | 501 | IHC | 20.2% | SC | 2.29 (1.61–3.24) | 8 | | Ahn et al. 2013 [22] | Korea | BC; ER+ | 1997–2007 | 81 | Microarray | 29.6% | SC | 6.80 (1.28–36.08) | 8 | | He et al. 2012 [12] | China | Cervical cancer; early-stage | 2002–2005 | 102 | IHC | 73.5% | SC | 1.11 (0.33–3.75) | 9 | | Li et al. 2013 [23] | China | Colon cancer; | 2001–2003 | 203 | IHC | 75.8% | HR | 3.62 (1.91–6.88) | 10 | | Chu et al. 2012 [24] | China | Colorectal cancer | 2002–2004 | 112 | IHC | 50.9% | HR | 2.03 (1.18–2.66) | 10 | |
Takata et al. 2014 [25] | Japan | Esophageal cancer | 2001–2007 | 174 | IHC | 50% | HR | 1.69 (1.06–2.75) | 10 | | Wang et al. 2013 [26] | China | Gallbladder cancer | 2002–2007 | 76 | IHC | 56.6% | SC | 1.81 (1.05–3.12) | 9 | | Okada et al. 2013 [14] | Japan | GC | 2001–2008 | 77 | IHC | 68.8% | HR | 3.9 (1.1–24.7) | 9 | | Hu et al. 2015 [27] | China | GC | NR | 40 | IHC | 65% | SC | 1.96 (0.27–14.19) | 7 | | Li et al. 2013 [28] | China | GC | 2007 | 103 | IHC | 78.6% | SC | 1.98 (0.84–4.66) | 9 | | Zhang et al. 2012 [29] | China | Glioblastoma | NR | 38 | IHC | 71.1% | SC | 2.70 (0.89–8.18) | 7 | | Xia et al. 2012 [13] | China | HCC | 1999–2001 | 306 | IHC | 65.7% | HR | 1.53 (1.10–2.12) | 10 | | Sun et al. 2011 [30] | China | HCC | 2001–2009 | 99 | IHC | 42.4% | SC | 3.59 (1.14–11.24) | 8 | | Sun et al. 2011 [31] | China | HCC | 2001–2008 | 150 | IHC | 59.3% | SC | 4.04 (2.02–8.09) | 9 | | Meng et al. 2015 [32] | China | HCC | 2006–2010 | 172 | IHC | 62.2% | SC | 1.87 (1.10–3.17) | 9 | | Jiang et al. 2011 [33] | China | Laryngeal SCC | 2002–2003 | 89 | IHC | 78.7% | SC | 1.35 (0.36–5.07) | 8 | | Xu et al. 2012 [34] | China | NSCLC | 2005–2008 | 201 | IHC | NR | HR | 1.96 (1.04–3.17) | 10 | | Chen et al. 2014 [35] | Taiwan | NSCLC | 1993–2004 | 117 | IHC | 60.7% | HR | 1.74 (1.06–2.86) | 10 | | Xu et al. 2013 [15] | China | NSCLC | 2005–2008 | 175 | IHC | 64% | HR | 1.899 (1.016–3.551) | 10 | | Yang et al. 2009 [36] | Korea | NSCLC | 2000–2004 | 69 | IHC | 37.7% | SC | 2.38 (0.74–7.68) | 8 | | Kong et al. 2014 [37] | China | NSCLC | 2004–2006 | 68 | IHC | 63.2% | HR | 2.95 (1.036–8.397) | 9 | | Wang et al. 2013 [38] | China | NSCLC; stage IIIb-IV | 2004–2007 | 162 | IHC | 71.6% | SC | 1.50 (1.01–2.22) | 9 | | Liu et al. 2011 [39] | China | NSCLC | 2004–2008 | 68 | IHC | 36.8% | SC | 2.36 (1.13–4.93) | 8 | | Yu et al. 2011 [40] | USA | MPNST | NR | 82 | IHC | 70.8% | HR | 1.93 (1.12–3.31) | 8 | | Priller et al. 2011 [41] | Germany | Medulloblastoma | NR | 130 | IHC | 33.8% | HR | 2.24 (1.05–4.77) | 9 | | Chen et al. 2014 [35] | Taiwan | Oral cancer | 1993–2004 | 110 | IHC | 43.6% | HR | 4.70 (2.50–8.87) | 10 | | Wen et al. 2014 [42] | China | OC | 2009–2011 | 158 | IHC | 63.9% | HR | 1.494 (1.007–2.215) | 10 | | Zhao et al. 2014 [43] | China | OC | 1987–2004 | 82 | IHC | 64.6% | SC | 1.12 (0.40–3.15) | 8 | | Chiu et al. 2015 [44] | Taiwan | OC | 1993–2010 | 106 | IHC | 44.3% | SC | 0.96 (0.43–2.16) | 9 | | Ning et al. 2014 [45] | China | PDA; stage II | 2002–2013 | 136 | IHC | 63.2% | HR | 1.270 (0.713–2.830) | 10 | | Xia et al. 2012 [46] | China | PDA | 2003–2007 | 80 | IHC | 66.3% | SC | 4.99 (1.50–16.55) | 8 | | Li et al. 2014 [47] | China | PDA | NR | 50 | IHC | 56% | SC | 1.61 (0.64–4.04) | 7 | | Xue et al. 2012 [48] | China | CCRCC | 2004–2008 | 83 | IHC | 45.8% | SC | 3.58 (1.20–10.74) | 8 | | Wu et al. 2013 [49] | China | CCRCC | 2006–2010 | 87 | IHC | 42.5% | HR | 3.97 (1.10–14.35) | 9 |
|
|
BC: breast cancer; GC: gastric cancer; HCC: hepatocellular carcinoma; SCC: squamous cell carcinoma; NSCLC: non-small-cell lung cancer; MPNST: malignant peripheral nerve sheath tumor; OC: ovarian cancer; PDA: pancreatic ductal adenocarcinoma; CCRCC: clear cell renal cell carcinoma; NR: Not Report; IHC: immunohistochemistry; HR: hazard ratio; SC: survival curve; ER(+): Estrogen Receptor (+).
|
